Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidoneHsiao‐Yen Ma(Gene Therapy Laboratory), Ning Ding(Gene Therapy Laboratory)European Respiratory JournalDecember 30, 202210.1183/13993003.00604-2022Cited by 23SaveCiteExport RISWatch citationsRelated PapersLOXL4, but not LOXL2, is the critical determinant of pathological collagen cross-linking and fibrosis in the lung|Science Advances|2023|48